Omeros Corporation (OMER) |
|
3.86 0.17 (4.61%)
|
03-24 16:00 |
|
Open: |
3.62 |
Pre. Close: |
3.69 |
|
High:
|
3.88 |
Low:
|
3.51 |
|
Volume:
|
210,069 |
Market Cap:
|
243(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:33 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 5.39  One year: 6.3 |
| Support: |
Support1: 3.64 Support2: 3.04 |
| Resistance: |
Resistance1: 4.61 Resistance2: 5.39 |
| Pivot: |
3.62 |
| Moving Average: |
MA(5): 3.59 MA(20): 3.66
MA(100): 3.06 MA(250): 3.58  |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 68.3 %D(3): 56.9 |
| RSI: |
RSI(14): 53.3 |
| 52-week: |
High: 7.75 Low: 1.74 |
| Average Vol(K): |
3-Month: 950 (K) 10-Days: 330 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OMER ] has closed below upper band by 19.1%. Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.88 - 3.89 |
3.89 - 3.91 |
|
Low:
|
3.47 - 3.49 |
3.49 - 3.5 |
|
Close:
|
3.83 - 3.86 |
3.86 - 3.88 |
|
Company Description |
|
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington. |
Headline News |
Fri, 17 Mar 2023
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt - Simply Wall St
Tue, 14 Mar 2023
Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript - Yahoo Finance
Mon, 13 Mar 2023
Omeros Corporation to Announce Fourth Quarter and Year End ... - Manchestertimes
Wed, 08 Feb 2023
Omeros (OMER): $200M Added To The Company's Balance Sheet ... - Seeking Alpha
Fri, 23 Dec 2022
How Will the Market React to Omeros Corporation (OMER) Stock Getting a Bullish Rating - InvestorsObserver
Wed, 09 Nov 2022
Omeros Corporation Reports Third Quarter 2022 Financial Results - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
63 (M) |
| Shares Float |
60 (M) |
|
% Held by Insiders
|
4 (%) |
|
% Held by Institutions
|
32.5 (%) |
|
Shares Short
|
8,520 (K) |
|
Shares Short P.Month
|
8,610 (K) |
Stock Financials |
|
EPS
|
-2.42 |
|
EPS Est Next Qtl
|
-0.32 |
|
EPS Est This Year
|
-1.3 |
|
EPS Est Next Year
|
-0.7 |
|
Book Value (p.s.)
|
-1.97 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
553.7 |
|
Return on Assets (ttm)
|
-35.8 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-0.48 |
|
EBITDA (p.s.)
|
-2.64 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-79 (M) |
|
Levered Free Cash Flow
|
-130 (M) |
Stock Valuations |
|
PE Ratio
|
-1.6 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
-1.97 |
|
Price to Sales
|
-8.08 |
|
Price to Cash Flow
|
-3.06 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
